Artificial Intelligence in Oncology

Artificial Intelligence in Oncology

Global Artificial Intelligence in Oncology Market to Reach US$16.3 Billion by 2030

The global market for Artificial Intelligence in Oncology estimated at US$3.9 Billion in the year 2024, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 26.9% over the analysis period 2024-2030. Hardware Component, one of the segments analyzed in the report, is expected to record a 24.3% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Software Component segment is estimated at 30.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 25.7% CAGR

The Artificial Intelligence in Oncology market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 25.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 24.2% and 23.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.9% CAGR.

Global Artificial Intelligence in Oncology Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing Cancer Diagnosis and Treatment?

Artificial Intelligence (AI) is transforming oncology by enabling earlier diagnosis, personalized treatment planning, and enhanced patient monitoring. Traditional cancer care often involves complex decision-making processes and labor-intensive workflows. AI addresses these challenges by leveraging machine learning (ML) algorithms, predictive analytics, and natural language processing (NLP) to analyze vast datasets and provide actionable insights.

In diagnostics, AI-powered imaging tools are revolutionizing cancer detection by analyzing radiology images, such as CT scans and MRIs, with unparalleled accuracy. These systems can identify subtle patterns indicative of malignancies, facilitating early detection and improving treatment outcomes. For instance, AI has demonstrated the ability to detect breast and lung cancers at earlier stages, reducing mortality rates significantly.

AI is also enhancing treatment planning by analyzing patient-specific data, including genetic profiles and tumor characteristics, to recommend personalized therapies. Predictive models evaluate the likely efficacy of treatments, enabling oncologists to make data-driven decisions. Additionally, AI systems assist in monitoring treatment progress and identifying potential side effects, ensuring that interventions are adjusted promptly to optimize patient care.

What Drives the Adoption of AI in Oncology?

The increasing prevalence of cancer and the urgent need for advanced diagnostic and treatment solutions are significant drivers of AI adoption in oncology. Cancer remains one of the leading causes of death globally, creating a critical demand for technologies that can improve early detection and enhance patient outcomes. AI tools provide healthcare professionals with the precision and efficiency required to meet these challenges.

The rise of precision medicine is another key factor. As cancer therapies become more targeted and personalized, AI is playing a pivotal role in analyzing complex datasets, such as genomic and proteomic information, to identify tailored treatment options. This capability is transforming oncology care, shifting the focus from one-size-fits-all approaches to individualized treatment strategies.

Furthermore, advancements in wearable devices and remote monitoring technologies are expanding the applications of AI in oncology. These tools generate real-time patient data, enabling continuous monitoring of symptoms and treatment responses. AI systems analyze this data to detect complications early and provide recommendations for proactive management, ensuring better outcomes for patients.

Can AI Improve Accessibility and Efficiency in Oncology Care?

AI is significantly enhancing accessibility and efficiency in oncology care by automating processes and enabling remote diagnostics. In regions with limited access to specialized oncologists, AI-powered tools bridge the gap by providing diagnostic support and treatment recommendations. Telemedicine platforms integrated with AI enable patients to receive expert consultations without traveling long distances, improving access to quality care.

AI also optimizes workflows in oncology departments by automating time-consuming tasks such as imaging analysis, pathology slide interpretation, and clinical documentation. This efficiency reduces the workload on healthcare providers, allowing them to focus on patient care. Additionally, AI systems prioritize high-risk cases, ensuring that patients requiring immediate attention are identified and treated promptly.

By enhancing the accuracy and speed of cancer diagnostics, AI minimizes delays in treatment initiation, a critical factor in improving survival rates. These advancements make oncology care more efficient and accessible, addressing disparities in cancer treatment and outcomes.

What’s Driving the Growth of the AI in Oncology Market?

The growth in the Artificial Intelligence in Oncology market is driven by several critical factors, reflecting its transformative potential in cancer care. The increasing availability of high-quality data, including medical images, patient records, and genomic profiles, is providing a foundation for AI-powered oncology solutions. These tools leverage data to improve diagnostic accuracy, personalize treatments, and monitor outcomes effectively.

Consumer behavior trends, such as the demand for proactive health management and personalized care, are encouraging healthcare providers to adopt AI technologies. Patients are seeking innovative solutions that enhance their treatment experiences and outcomes, driving investments in AI-powered oncology tools.

Additionally, regulatory support for AI-based medical devices and increasing investments in oncology research are fueling market growth. Governments and healthcare organizations are promoting the adoption of AI to improve cancer care delivery and reduce healthcare costs. These factors, combined with ongoing advancements in AI algorithms and hardware, are propelling the rapid expansion of the AI in Oncology market, positioning it as a cornerstone of future innovation in cancer diagnostics and treatment.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Hardware Component, Software Component, Services Component); Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Other Cancer Types); Application (Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application, Immunotherapy Application); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

• Azra AI
• ConcertAI LLC
• GE Healthcare
• IBM Corporation
• Intel Corporation
• Median Technologies
• Mercurius Health
• NVIDIA Corporation
• Quest Diagnostics, Inc.
• Siemens Healthineers AG

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.